Browse studies
Find your next paid study
4 recruiting studies matching your filters
Phase 3
An Open-label, Non-randomized Extension Study to Evaluate the Long-term Efficacy, Safety and Tolerability of Iptacopan (LNP023) in C3 Glomerulopathy or Idiopathic Immune-complex-membranoproliferative Glomerulonephritis
This is an open-label extension study to evaluate the long-term efficacy, safety and tolerability of iptacopan in subjects with C3 glomerulopathy or idiopathic…
C3 GlomerulopathyImmune-complex-membranoproliferative Glomerulonephritis
Novartis PharmaceuticalsNCT03955445
Phase 3
A Multicenter Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Zigakibart in Adults With Primary IgA Nephropathy.
The purpose of this study is to determine if zigakibart is safe and effective for long-term use in patients with immunoglobulin A nephropathy (IgAN). This is a…
Kidney DiseasesKidney Diseases, ChronicUrological Diseases+5 more
Novartis PharmaceuticalsNCT06858319
Clinical Phenotyping Resource and Biobank Core of the Michigan O'Brien Renal Center
Chronic kidney disease (CKD) affects approximately 26 million Americans and disproportionately manifests in specific race and ethnic groups. Patients burdened …
Chronic Kidney DiseaseGlomerulopathy
University of MichiganNCT01016613
A Mobile App-Based, Prospective, Observational Study to Evaluate Disease Burden and Treatment Patterns in C3 Glomerulopathy (C3G) in the US
The study aims to longitudinally capture the full spectrum of symptoms, treatment utilization, and overall Health-related Quality of Life (HRQoL) experienced b…
C3 Glomerulopathy
Novartis PharmaceuticalsNCT07029542